A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351

A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.

开始日期2011-12-01

申办/合作机构

Janssen Alzheimer Immunotherapy Research & Development LLC

[+1]

NCT01369225 / Completed临床1期

A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001

This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

开始日期2011-07-01

申办/合作机构

Pfizer Inc.

[+1]

NCT01227564 / Completed临床2期

A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.

This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.

开始日期2011-02-01

申办/合作机构

Pfizer Inc.

[+1]

100 项与 Janssen Alzheimer Immunotherapy Research & Development LLC 相关的临床结果

登录后查看更多信息

0 项与 Janssen Alzheimer Immunotherapy Research & Development LLC 相关的专利（医药）

登录后查看更多信息

项与 Janssen Alzheimer Immunotherapy Research & Development LLC 相关的文献（医药）

2021-06-01·BMJ Open4区 · 医学

Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy

4区 · 医学

ArticleOA

作者: Watermeyer, Tamlyn ; Kafetsouli, Dimitra ; Raghavan, Nandini ; McLellan-Young, Heather ; Kivipelto, Miia ; Di, Jianing ; Cohn, Martin ; Reglinska-Matveyev, Natalia ; Middleton, Lefkos ; Udeh-Momoh, Chinedu T ; Arrighi, Michael ; Car, Josip ; Bassil, Darina ; Giannakopoulou, Parthenia ; Crispin, Jennifier ; Ritchie, Craig W ; Price, Geraint ; Ward, Heather ; Lakey, Kristina ; Majeed, Azeem ; Ropacki, Michael ; de Jager Loots, Celeste A ; Ketter, Nzeera ; Bracoud, Luc ; Scott, David ; Ritchie, Karen ; Robb, Catherine ; Perera, Dinithi ; Chowdary Seemulamoodi, Yellappa ; Fogle, Michael ; Saad, Ziad ; Baker, Susan ; Perneczky, Robert ; Novak, Gerald ; Brashear, Robert ; Lisa, Curry

IntroductionThe Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy (CPSS), sponsored by Janssen Pharmaceutical Research & Development LLC, is an Alzheimer’s disease (AD) biomarker enriched observational study that began 3 July 2015 CPSS aims to identify and validate determinants of AD, alongside cognitive, functional and biological changes in older adults with or without detectable evidence of AD pathology at baseline.Methods and analysisCPSS is a dual-site longitudinal cohort (3.5 years) assessed quarterly. Cognitively normal participants (60–85 years) were recruited across Greater London and Edinburgh. Participants are classified as high, medium (amnestic or non-amnestic) or low risk for developing mild cognitive impairment–Alzheimer’s disease based on their Repeatable Battery for the Assessment of Neuropsychological Status performance at screening. Additional AD-related assessments include: a novel cognitive composite, the Global Preclinical Alzheimer’s Cognitive Composite, brain MRI and positron emission tomography and cerebrospinal fluid analysis. Lifestyle, other cognitive and functional data, as well as biosamples (blood, urine, and saliva) are collected. Primarily, study analyses will evaluate longitudinal change in cognitive and functional outcomes. Annual interim analyses for descriptive data occur throughout the course of the study, although inferential statistics are conducted as required.Ethics and disseminationCPSS received ethical approvals from the London—Central Research Ethics Committee (15/LO/0711) and the Administration of Radioactive Substances Advisory Committee (RPC 630/3764/33110) The study is at the forefront of global AD prevention efforts, with frequent and robust sampling of the well-characterised cohort, allowing for detection of incipient pathophysiological, cognitive and functional changes that could inform therapeutic strategies to prevent and/or delay cognitive impairment and dementia. Dissemination of results will target the scientific community, research participants, volunteer community, public, industry, regulatory authorities and policymakers. On study completion, and following a predetermined embargo period, CPSS data are planned to be made accessible for analysis to facilitate further research into the determinants of AD pathology, onset of symptomatology and progression.Trial registration numberThe CHARIOT:PRO SubStudy is registered with clinicaltrials.gov (NCT02114372). Notices of protocol modifications will be made available through this trial registry.

2018-12-12·Journal of Alzheimer's Disease3区 · 医学

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

3区 · 医学

Article

作者: Sperling, Reisa ; Salloway, Stephen P. ; Bangen, Katherine ; Brashear, H. Robert ; Bogert, Jennifer ; Di, Jianing ; Ketter, Nzeera

BACKGROUNDAmyloid-related imaging abnormalities with effusion or edema (ARIA-E) reported in patients with mild-to-moderate Alzheimer's disease in bapineuzumab phase III studies.OBJECTIVESAssess symptoms, clinical severity, and ARIA-E outcomes, and to evaluate effects on cognition and function.METHODSA centralized systematic sequential locked procedure and scoring system for assessment of magnetic resonance imaging scans in 1,331 APOE ɛ4 noncarriers and 1,121 carriers was conducted by experienced and trained pairs of neuroradiologists.RESULTSTreatment-emergent ARIA-E occurred in 15.8% of bapineuzumab and 0.8% placebo-treated patients. In all treated APOE ɛ4 noncarriers, the percentage of patients with ARIA-E was 5.6%, 13.4%, and 19.9% in the 0.5, 1.0, and 2.0 mg/kg groups respectively, and the incidence of symptomatic ARIA-E was 1.5%, 1.5%, and 7.8%, respectively. In carriers, ARIA-E occurred in 21.2% in the 0.5 mg/kg group, and symptomatic ARIA-E occurred in 2.4%. The clinical severity of ARIA-E in those patients in whom it was detected during the study was mild in 57.1%, 61.3%, and 50.0% of cases in 0.5, 1.0, and 2.0 mg/kg noncarriers respectively, and in 73.8% of cases in 0.5 mg/kg carriers. Vascular risk factors did not appear to increase susceptibility to ARIA-E. Rate of decline in cognition and function measured by changes in ADAS-Cog/11 and DAD total scores did not meaningfully differ in patients with ARIA-E versus those without ARIA-E. Extent of cognitive decline was similar over all visit intervals.CONCLUSIONSOverall, ARIA-E was mild and asymptomatic. ARIA-E did not demonstrate clinically meaningful acute or chronic impact on cognition or function.Registration: NCT00574132 (Bapineuzumab-301), NCT00575055 (Bapineuzumab-302).

2018-03-01·European Radiology2区 · 医学

The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer’s patients: An interobserver study

2区 · 医学

Article

作者: Arrighi, Michael H ; Ingala, Silvia ; Wattjes, Mike P ; Brashear, Robert H ; Sanchez, Esther ; Purcell, Derk ; van Schijndel, Ronald A ; Barkhof, Frederik ; Martens, Roland M ; Bechten, Arianne ; Machado, Vania B ; de Jong, Marcus C

BACKGROUNDImmunotherapeutic treatments targeting amyloid-β plaques in Alzheimer's disease (AD) are associated with the presence of amyloid-related imaging abnormalities with oedema or effusion (ARIA-E), whose detection and classification is crucial to evaluate subjects enrolled in clinical trials.PURPOSETo investigate the applicability of subtraction MRI in the ARIA-E detection using an established ARIA-E-rating scale.METHODSWe included 75 AD patients receiving bapineuzumab treatment, including 29 ARIA-E cases. Five neuroradiologists rated their brain MRI-scans with and without subtraction images. The accuracy of evaluating the presence of ARIA-E, intraclass correlation coefficient (ICC) and specific agreement was calculated.RESULTSSubtraction resulted in higher sensitivity (0.966) and lower specificity (0.970) than native images (0.959, 0.991, respectively). Individual rater detection was excellent. ICC scores ranged from excellent to good, except for gyral swelling (moderate). Excellent negative and good positive specific agreement among all ARIA-E imaging features was reported in both groups. Combining sulcal hyperintensity and gyral swelling significantly increased positive agreement for subtraction images.CONCLUSIONSubtraction MRI has potential as a visual aid increasing the sensitivity of ARIA-E assessment. However, in order to improve its usefulness isotropic acquisition and enhanced training are required. The ARIA-E rating scale may benefit from combining sulcal hyperintensity and swelling.KEY POINTS• Subtraction technique can improve detection amyloid-related imaging-abnormalities with edema/effusion in Alzheimer's patients. • The value of ARIA-E detection, classification and monitoring using subtraction was assessed. • Validation of an established ARIA-E rating scale, recommendations for improvement are reported. • Complementary statistical methods were employed to measure accuracy, inter-rater-reliability and specific agreement.

100 项与 Janssen Alzheimer Immunotherapy Research & Development LLC 相关的药物交易

登录后查看更多信息

100 项与 Janssen Alzheimer Immunotherapy Research & Development LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Vanutide cridificar ( APP )	阿尔茨海默症更多	终止
Bapineuzumab ( APP )	阿尔茨海默症更多	终止
QS-21	阿尔茨海默症更多	终止
Alzheimer disease vaccine(Elan Pharmaceuticals, LLC) ( APP )	阿尔茨海默症更多	终止
AAB-003 ( APP )	阿尔茨海默症更多	无进展